Clinical trial for groundbreaking Alzheimer's disease drug begins in Middle Tennessee
A Middle Tennessee neurology office is conducting clinical trials for a potentially groundbreaking Alzheimer’s drug, BenfoTeam, which uses a lab-made version of vitamin B1 to possibly slow down or reverse the disease. The trial, focusing on cognitive function and daily routine activities, is open to people aged 50-89 with mild memory concerns or mild Alzheimer’s, not in long-term nursing care, and willing to participate in an 18-month program.
Related Clinical Trials
Highlighted Terms
Related News
A national clinical trial, funded by the NIH, is testing a synthetic vitamin B1 (benfotiamine) developed by Burke Neurological Institute for treating mild cognitive impairment and early Alzheimer's disease. The trial, involving 50 sites across the U.S., aims to evaluate benfotiamine's effects on cognitive function and its potential to slow cognitive decline in participants aged 50-89. The study builds on research showing benfotiamine's ability to improve memory and reduce plaques, tangles, inflammation, and oxidative stress in animal models.
A Middle Tennessee neurology office is conducting clinical trials for a potentially groundbreaking Alzheimer’s drug, BenfoTeam, which uses a lab-made version of vitamin B1 to possibly slow down or reverse the disease. The trial, focusing on cognitive function and daily routine activities, is open to people aged 50-89 with mild memory concerns or mild Alzheimer’s, not in long-term nursing care, and willing to participate in an 18-month program.
A national clinical trial, funded by NIH, tests benfotiamine, a synthetic vitamin B1, for treating mild cognitive impairment and early Alzheimer's disease. The trial, led by Burke Neurological Institute, UC San Diego, and Columbia University, aims to evaluate benfotiamine's cognitive effects and safety profile. Enrollment targets 406 participants aged 50-89 across 50 U.S. sites.